Market Intelligence, Clinical Progress, and High-Purity Reagents for Alzheimer's Disease and Tauopathy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TAU-targeted drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TAU Mutant Recombinant Proteins (P301L, V337M, R406W) and isoforms (0N3R to 2N4R); Pathogenic FTD variants & WT; High purity (>95%), Monomeric/Fibrillar forms available. Endotoxin <1EU/ug. Sequence Verified. | View TAU Products |
| Phospho-Antigen | Phosphorylated TAU (pT181, pS396, pS404, pT217); HEK293 Expressed, Site-specific phosphorylation confirmed by Mass Spec. Theoretical MW verification. | View TAU Products |
| Gene Delivery | TAU-EGFP Lentivirus Premade Particles (full-length MAPT ORF, 2N4R isoform) for stable neuronal cell line construction (SH-SY5Y/HEK293). P301L/P301S variants available. Endotoxin Controlled. | View TAU Products |
| Benchmark Ab | Anti-TAU Antibody (Semorinemab Epitope); Recombinant human IgG4 positive control; N-terminal specific (aa 1-230). Sequence verified benchmarks for affinity assays. | View TAU Products |
| Validator | MAPT siRNA Set (3 unique targets); For knockdown verification in aggregation assays; >85% transfection efficiency validated. | View TAU Products |
| Related Target A | APP (Amyloid Precursor Protein); Synergistic pathway in Alzheimer's; Required for combination therapy studies. | View APP Products |
| Related Target B | MAP2 (Microtubule-Associated Protein 2); Off-target screening necessity; High homology neuronal cytoskeleton protein. | View MAP2 Products |
| Related Target C | GSK3B (Glycogen Synthase Kinase 3 Beta); Primary TAU kinase; Upstream target for phosphorylation inhibition strategies. | View GSK3B Products |
| Related Target D | TREM2; Microglial activation pathway synergistic with Tau clearance. | View TREM2 Products |
| Related Target E | APOE; Genetic risk factor intersecting with Tau pathology. | View APOE Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Aggregation State Maintenance (Monomer vs Fibril) | Pre-validated Monomeric (HEPES buffered) and Fibrillar (Thioflavin T confirmed) protein lots with >95% purity |
| Iisoform & Mutant Specificity Screening | Specific Isoforms (0N3R to 2N4R) and Clinical Mutants (P301L/S) available with >95% purity and Theoretical MW confirmation |
| Cross-species Translation (Mouse/Human/Cyno) | Ortholog proteins with sequence verified homology; Critical for transgenic model correlation (hTau mice) |
| Phosphorylation Site Specificity | Site-specific phospho-TAU standards (pT181, pT217, pS396) for epitope binning assays |
| Intracellular Target Access (Antibody uptake) | Lentivirus-based stable neuronal lines (SH-SY5Y/HEK293) expressing cytoplasmic TAU for internalization monitoring |
| Cell Model Construction for Intracellular Targets | Lentivirus Premade Particles for stable HEK293/SH-SY5Y cell line generation, preserving native intracellular environment |
| Microglial Engagement (ADCC/Phagocytosis) | Clinical Benchmark Antibodies (IgG4/IgG1 isotype controls) included for Fc-effector comparison |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) strictly sequence verified for use as assay positive controls |
| Target Validation & False Positives | Validated siRNA included for precise specificity checks and degradation assay baseline establishment |
| Genetic Validation | MAPT siRNA Set included for target specificity confirmation in seeding assays |
Live TAU R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TAU-targeting therapeutics is intensifying following the validation of amyloid clearance strategies. Major players are shifting from monotherapy to combination approaches targeting both amyloid plaques and neurofibrillary tangles. As first-generation anti-tau antibodies (Semorinemab, Gosuranemab) complete Phase 2, the next wave of R&D is targeting epitope-specific strategies (N-terminal vs. mid-domain/MTBR) and microglial-mediated clearance mechanisms. Additionally, novel modalities such as Antisense Oligonucleotides (ASOs, e.g., IONIS-MAPT by Ionis/Biogen) and PROTAC degraders (e.g., Arvinas) are gaining traction to reduce intracellular tau load. Blood-brain barrier (BBB) penetrance technologies (e.g., Roche's Brainshuttle) and bispecific formats are becoming standard prerequisites for next-generation candidates. The emergence of plasma p-Tau217 as a diagnostic biomarker is simultaneously driving demand for calibrated research reagents and accelerating patient stratification in clinical trials.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| N-terminal Anti-TAU mAb | Roche (Semorinemab), UCB | Alzheimer's Disease (Prodromal) | Epitope mapping against monomeric vs. aggregated forms; Need high-purity N-terminal domain proteins |
| Phospho-TAU Specific mAb | Eli Lilly, Biogen | Progressive Supranuclear Palsy (PSP) | Phospho-site specific competition assays; Require pT181/pT217 calibrated standards |
| Bispecific / BBB-shuttles | Roche (Brainshuttle), Denali | Neurodegeneration | Receptor Co-binding Assays (Need Human/Cyno cross-reactive antigens) |
| ASO / Gene Therapy | Ionis/Biogen, Biogen | Frontotemporal Dementia (FTD), Early-onset AD | Target engagement validation; Need MAPT knockdown cell lines (Lentivirus compatible) |
| Small Molecule Aggregase Inhibitor | TauRx, AC Immune | Mild Cognitive Impairment | Thioflavin T aggregation assays; Require fibrillar TAU seeds with verified β-sheet content |
| Active Vaccine | AC Immune (AADvac1), Janssen | Alzheimer's Disease | Immunogenicity testing; Need carrier protein-conjugated TAU peptides |
| PROTACs / Small Mol Degraders | Arvinas, AC Immune | Tauopathies | Degradation Assays (Need P301L Lentivirus for stable expression) |
Note: Some candidates span multiple categories. For simplicity, key players and indications are listed per primary modality.